Literature DB >> 26996727

Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.

S-L Yang1, L-P Liu2, S Yang1, L Liu1, J-W Ren1,3, X Fang4, G G Chen1,3, P B S Lai1.   

Abstract

BACKGROUND: While the majority of studies report that a raised serum α-fetoprotein (AFP) level before operation is associated with a high risk of recurrence and death in patients who undergo hepatectomy for hepatocellular carcinoma (HCC), results are conflicting. The aim of this study was to assess the prognostic value of AFP.
METHODS: Serum AFP levels were measured in patients with hepatitis-associated HCC who underwent hepatectomy between 1995 and 2012. Kaplan-Meier and multivariable analyses were performed to identify risk factors for overall and disease-free survival. Univariable and multivariable Cox proportional hazards regression was used to evaluate the predictive value of AFP. Receiver operating characteristic (ROC) curves were generated to identify the AFP level that had the highest accuracy in discriminating between survivors and non-survivors.
RESULTS: Some 376 patients with hepatitis B virus (HBV)-associated HCC were included in the study. The overall survival rate was 58·8 per cent in patients with an AFP level of 400 ng/ml or less compared with 40·4 per cent for those with a level exceeding 400 ng/ml (P = 0·001). AFP concentration above 400 ng/ml was an independent risk factor for shorter disease-free and overall survival after surgery. ROC analysis indicated that the optimal cut-off values for AFP varied for different subtypes of HCC. The sensitivity and specificity were lower with areas under the ROC curve of less than 0·600. An AFP level greater than 400 ng/ml was not sensitive enough to predict the prognosis in patients with an HCC diameter smaller than 3 cm.
CONCLUSION: A serum AFP level above 400 ng/ml predicts poor overall and recurrence-free survival after hepatectomy in patients with HBV-associated HCC. AFP is not a strong prognostic marker given its poor discriminatory power, with low sensitivity and specificity.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26996727     DOI: 10.1002/bjs.10093

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  44 in total

1.  Postoperative Albumin-Bilirubin Grade Change Predicts the Prognosis of Patients with Hepatitis B-Related Hepatocellular Carcinoma Within the Milan Criteria.

Authors:  Chuan Li; Xiao-Yun Zhang; Wei Peng; Tian-Fu Wen; Lu-Nan Yan; Bo Li; Jia-Yin Yang; Wen-Tao Wang; Ming-Qing Xu
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

2.  Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus.

Authors:  John R Bergquist; Amy Y Li; Chris S Javadi; Ranjit S Chima; Joseph S Frye; Brendan C Visser
Journal:  Dig Dis Sci       Date:  2020-11-03       Impact factor: 3.199

3.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

4.  Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area.

Authors:  Andra-Iulia Suceveanu; Ioan Sergiu Micu; Gabriela-Izabela Baltatescu; Lucian Cristian Petcu; Nicolae Dobrin; Costel Brinzan; Cornelia Nitipir; Laura Mazilu; Florin Botea; Vlad Herlea; Felix Voinea; Adrian Paul Suceveanu
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

5.  Hepatectomy Combined with Diaphragmatic Resection for Hepatocellular Carcinoma with Diaphragmatic Involvement: A Propensity Score-Matched Analysis.

Authors:  Tatsuya Orimo; Toshiya Kamiyama; Kenji Wakayama; Shingo Shimada; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Hirofumi Kamachi; Akinobu Taketomi
Journal:  Ann Surg Oncol       Date:  2020-06-25       Impact factor: 5.344

6.  Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.

Authors:  Rui Liao; De-Wei Li; Cheng-You Du; Ming Li
Journal:  J Gastrointest Surg       Date:  2018-05-18       Impact factor: 3.452

7.  Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus.

Authors:  Xiao-Hui Wang; Bing Liao; Wen-Jie Hu; Cai-Xue Tu; Cai-Ling Xiang; Sheng-Hua Hao; Xian-Hai Mao; Xiao-Ming Qiu; Xiao-Jun Yang; Xiao Yue; Ming Kuang; Bao-Gang Peng; Shao-Qiang Li
Journal:  Oncologist       Date:  2020-08-06       Impact factor: 5.837

8.  Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients.

Authors:  Yang-Xun Pan; Xu-Qi Sun; Zi-Li Hu; Wa Xie; Ke-Xin Nie; Ai-Ping Fang; Ying-Yao Zhang; Yi-Zhen Fu; Jin-Bin Chen; Jun-Cheng Wang; Xin Wang; Yao-Jun Zhang; Dan-Dan Hu; Min-Shan Chen
Journal:  J Hepatocell Carcinoma       Date:  2021-06-25

9.  Elevated Preoperative Serum Gamma-glutamyltranspeptidase Predicts Poor Prognosis for Hepatocellular Carcinoma after Liver Transplantation.

Authors:  Shun-Jun Fu; Qiang Zhao; Fei Ji; Mao-Gen Chen; Lin-Wei Wu; Qing-Qi Ren; Zhi-Yong Guo; Xiao-Shun He
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

10.  A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma.

Authors:  Yue Yin; Jian-Wen Cheng; Fei-Yu Chen; Xu-Xiao Chen; Xin Zhang; Ao Huang; De-Zhen Guo; Yu-Peng Wang; Ya Cao; Jia Fan; Jian Zhou; Xin-Rong Yang
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.